An interventional study of Blood sample in Rheumatic Diseases and Mood Disorders, sponsored by Centre Hospitalier Universitaire de Besancon. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-09.
Sponsored by Centre Hospitalier Universitaire de Besancon · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Rheumatic Diseases with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Rheumatic Diseases · France.
Among the 25 studies in Rheumatic Diseases with a site in France, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 with no phase, and was the 18th registered.
264 studies on the registry are indexed under Rheumatic Diseases; 60 are open to participants now.
Browse Rheumatic Diseases studies →8 of the 25 studies in Rheumatic Diseases with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 41 Rheumatic Diseases studies recruiting now, 18 (44%) set no upper age limit and 12 (29%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2021.
This study's planned enrollment of 108 is close to the median of 100 across 167 interventional studies indexed under Rheumatic Diseases.
Median enrollment 123 across the 10 interventional studies, 397 across the 15 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 25 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Besancon is the lead sponsor of 450 studies on the registry; 97 are open to participants now.
Centre Hospitalier Universitaire de Besancon has 1 study filed under Rheumatic Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Rheumatic Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07005804Lille Catholic UniversityCalcium Pyrophosphate Deposition (CPPD) Disease | 2027-05 |
| NCT07469787Assistance Publique - Hôpitaux de ParisCompassionate Care and Organization of Healthcare Services for a Successful Transition in Rheumatology | 2027-08-26 |
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Rheumatic Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic inflammatory rheumatic diseases (CIRD) affect many organ systems. Painful sensations within the joints spine, hand and foot deformities, low quality of life and psychosocial status in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis can lead to the development of anxiety and depression. Prevalences of anxiety increase in patients suffering of CIRD, compared with healthy individuals. Another connection has been identified by the links between depression and systemic inflammation. It is proven that higher plasma levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa) affect neurotransmitter metabolism, with influence on patients mood. The purpose of EMOTION study is therefore to analyze thymic variation under TNFa therapy, as treatment of CIRDs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients presenting a chronic inflammatory rheumatic disease (rheumatoid arthritis, spondyloarthritis or psoriatic arthritis), requiring anti-TNFa therapy and with a QIDS SR-16 (QIDS-SR 16-Quick Inventory of Depressive Symptomatology-Self Reported 16 items) score between 6 and 19
Other: Blood sample
Blood sample (20mL) for pro-inflammatory cytokines assay
Severity of depressive symptoms
Score achieved on the validated self-report questionnaire (QIDS SR16) evaluating the severity of depressive symptoms
Time frame: 1 month after initiation of anti-TNFa therapy
Evaluation of disease activity
Evaluation with CPDAI (Composite Psoriatic Disease Activity Index) (minimum value: 0; maximum value: 15; increases with the activity of the disease)
Time frame: 3 months after initiation of anti-TNFa therapy
Evaluation of disease activity
Evaluation with DAS28 (Disease Activity Score 28-joint count) (minimum value: 0; maximum value: 9.4; increases with the activity of the disease)
Time frame: 3 months after initiation of anti-TNFa therapy
Evaluation of disease activity
Evaluation with BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) (minimum value: 0 (no disease activity); maximum value: 10 (very active disease))
Time frame: 3 months after initiation of anti-TNFa therapy
Evaluation of disease activity
Evaluation with ASDAS (Ankylosing Spondylitis Disease Activity Score) (minimum value: 0 (no disease activity); value \>3.5 between : very high disease activity)
Time frame: 3 months after initiation of anti-TNFa therapy
Evaluation of Fatigue
Evaluation with Functional Assessment of Chronic Illness Therapy
Time frame: 3 months after initiation of anti-TNFa therapy
Evaluation of Pleasure
Evaluation with Snaith-Hamilton pleasure scale (minimum value: 0 (no disease activity); maximum value: 14 (very active disease)). A higher total SHAPS score indicated higher levels of anhedonia.
Time frame: 3 months after initiation of anti-TNFa therapy
Plan to share: No
No publications or documents are linked to this record.
Started May 2021 (actual). Primary completion is estimated for Nov 2025, 54 months after the start.
Of 72 non-industry interventional studies with no phase under Rheumatic Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 54 months is above that.
Counting every sponsor, half of 74 studies reached it within 26 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Besancon →